Skip to Content

Prepared for AstraZeneca

You're scaling toward $80bn by 2030, tripling parenteral volume and bringing 20 new medicines to patients along the way.  As a world-class, integrated CDMO with more than five decades of experience and 90+ successful product launches a year, PCI Pharma Services is ready now to support your programs across vials, prefilled syringes, and autoinjector/pen devices with the expertise, science, and capacity to simplify the complex.

The volume is coming.
We've been anticipating it.

Your global network strategy points to 104 upcoming programs, 60% of them on parenteral platforms. Vials are the single largest primary container format by count, with syringe and cartridge volumes rising as high-growth formats and cold chain demand expected to double. Stable and progressive, we're always anticipating the future needs of our clients, and confirmed CMO capacity across the industry hasn't kept pace with growth like this.

$1B

1Billion invested in sterile fill finish & Drug-Device combination infrastructure

250

US device assembly capacity of 250 million units per year

400 p/m

New isolator vial and lyophilization line capable of producing batch sizes of up to 300,000 vials at 400 units per minute

$1 billion invested

That's precisely the gap PCI has spent the last several years closing with more than $1 billion invested in sterile fill-finish and drug-device combination infrastructure across the US and Europe, engineered for exactly the formats and volumes your pipeline demands. Rooted in experience, our industry-leading heritage engenders the trust to deliver the future legacy AstraZeneca is building.

  • $1Billion invested in sterile fill finish & Drug-Device combination infrastructure
  • US device assembly capacity of 250 million units per year
  • New isolator vial and lyophilization line capable of producing batch sizes of up to 300,000 vials at 400 units per minute
  • 2 New isolator PFS/Cartridges lines (US & EU) adding 60M units/year extra capacity in our Network

The formats you need, at the scale you need them.

Whichever combination of vials, prefilled syringes, cartridges and autoinjector or pen devices your products require, PCI brings unparalleled knowledge, know-how, and expertise across our global integrated network with the flexibility to shift format mix as your programs evolve from clinical to commercial scale.

Vials

High-speed, and lyophilized; engineered at true commercial scale.

  • Isolator-based aseptic filling up to 400 vials per minute, batch sizes up to 300,000 units, with Annex 1-compliant containment across our newest facilities
  • World-class expertise in the science of lyophilization, with twin 40m2 lyophilizers and automated loading/unloading for complex biologics
  • Comprehensive clinical and commercial vial packaging and labelling expertise managing light and oxygen-sensitive products, temperature-controlled cold chain and low-humidity environments with precision. 

Prefilled Syringes

From 2,000 to 300,000 syringes per batch

  • Specialist capabilities including high-volume prefilled syringe filling, scaling from low/mid volume through high-volume production under one roof.
  • Multi-platform technology supporting complex biologics, peptides, and small molecules in ready-to-use syringe formats
  • An integrated path from sterile fill straight into device assembly, package design, and testing coordinated across our integrated network 
  • Adding 60M units per year in prefilled syringe/cartridge capacity in the US & EU

Autoinjectors & Pen Devices

Device-agnostic assembly, engineered for the formats you use today and the ones you'll need tomorrow.

  • Isolator-based cartridge filling across our US and EU network, for an integrated fill-to-device pathway with no third-party handoff 
  • Multi-platform technology with rapid changeover across the majority of current formats
  • Expanding device assembly capacity toward 250M+ units per year
  • Extensive cold chain capabilities to support drug-device combination products, backed by in-house performance testing and human factor studies
  • Lifecycle Assessments and Sustainable package design to reduce environmental impact.

Invested where it matters most 
— capacity, quality, and reach

Our teams can support AstraZeneca with world-class CDMO solutions from development through commercialization and beyond with quality and safety built into every step of the product pathway. 

As a premium CDMO, we hold ourselves to the highest standards, and we've made significant, sustained investments to strengthen delivery, quality, and reach across our integrated network. AstraZeneca’s strategy calls for regional manufacturing and packaging capability in both the EU and US for every launch. PCI's network is built exactly that way, with free trade zone capabilities and supply chain expertise that give your products regionally secure supply without sacrificing a single, unified quality standard.

Brilliant minds behind your program. Every step of the way.

Tom DeWeerdt

Chief Financial Officer.

Angi Calkins

Chief People and Sustainability Officer

Jeannie Metzinger

Chief Compliance and Quality Officer

Gil Valadez

Chief Operating Officer

Tim Roberts

Chief Commercial Officer

John Cullivan

Chief Corporate Development Officer

John Ross

President, Development and Manufacturing Services